New Therapy for Breast Cancer Granted FDA Approval
May 24th 2019Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
Read More
Recommendations for Counseling Traveling Patients with Diabetes
May 23rd 2019According to the ADA, best practice is to pack at least twice as much medications and glucose testing supplies as normally needed to minimize complications due to travel delays or lost luggage.3 Many manufacturers of insulin pumps will provide a loaner for international travel.
Read More
Drugs of the Future Start with Regulatory Affairs
May 23rd 2019Regulatory affairs is another frontier for pharmacists to explore, and pharmacists are just scratching the surface of the opportunities in this area. In this interview with pharmacist Brendan Doran of CTI Clinical Trial & Consulting, he touches on the many phases of the drug life cycle with an emphasis on the process of bringing a drug to regulatory bodies for market approval, and gives a look into some of the current and emerging roles available in regulatory affairs.
Read More
Investigational Inhalational Therapy Shows Benefits Over Standard Asthma Treatment in Study
May 22nd 2019The new phase 2 data for an investigational once-daily, fixed dose combination currently in development for the treatment of inadequately controlled asthma was presented at the 2019 Annual International Congress of the American Thoracic Society (ATS) in Dallas.
Read More